Loading...
•
Dec 31, 2020
CRISPR Therapeutics Q4 2020 Earnings Report
CRISPR Therapeutics' fourth quarter results were negatively impacted by decreased collaboration revenue, offset by R&D and G&A expenses.
Key Takeaways
CRISPR Therapeutics reported a net loss of $107.0 million for the fourth quarter of 2020, compared to a net income of $30.5 million for the fourth quarter of 2019. The company's cash, cash equivalents, and marketable securities totaled $1,690.3 million as of December 31, 2020.
More than 20 patients have been dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; completion of enrollment in both trials is expected in 2021
Additional data from CTX110™ trial expected to report in 2021, along with top-line data from CTX120™ and CTX130™
Total collaboration revenue was $0.2 million for the fourth quarter of 2020 compared to $77.0 million for fourth quarter of 2019
Net loss was $107.0 million for the fourth quarter of 2020 compared to income of $30.5 million for the fourth quarter of 2019
CRISPR Therapeutics
CRISPR Therapeutics
CRISPR Therapeutics Revenue by Segment
Revenue by Segment
Collaboration Revenue
CapyFin.comGrant Revenue
CapyFin.com Forward Guidance
CRISPR Therapeutics anticipates completing enrollment in CTX001 clinical trials, providing data updates on allogeneic CAR-T programs, bringing the large-scale manufacturing facility online, and building commercial infrastructure in 2021.
Positive Outlook
- Complete enrollment in the CTX001 clinical trials
- Provide data updates on our three clinical allogeneic CAR-T programs
- Make meaningful progress in bringing our large-scale manufacturing facility online
- Building our commercial infrastructure
- Advance programs as we enter a new phase of growth for the company
Revenue & Expenses
Visualization of income flow from segment revenue to net income